Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623000624684
Ethics application status
Approved
Date submitted
24/05/2023
Date registered
7/06/2023
Date last updated
11/08/2024
Date data sharing statement initially provided
7/06/2023
Type of registration
Retrospectively registered

Titles & IDs
Public title
A pilot trial of single versus dual diuretic therapy in the intensive care unit
Scientific title
A pilot trial of single versus dual diuretic therapy in the intensive care unit
Secondary ID [1] 309727 0
nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
critical care
 330118 0
Condition category
Condition code
Renal and Urogenital 327000 327000 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Throughout the patient's admission to the intensive care unit and at the time the treating intensive care doctor has decided to administer an intravenous diuretic, a single intravenous bolus of 40 mg furosemide and 500 mg acetazolamide will be given with the effects monitored via medical record audit.
Intervention code [1] 326166 0
Treatment: Drugs
Comparator / control treatment
Throughout the patient's admission to the intensive care unit and at the time the treating intensive care doctor has decided to administer an intravenous diuretic, a single intravenous bolus of 40 mg furosemide will be given with the effects monitored via medical record audit.
Control group
Active

Outcomes
Primary outcome [1] 334859 0
urinary output after diuretic administration
Timepoint [1] 334859 0
Total urinary outcome in the 6 hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.
Secondary outcome [1] 422259 0
Serum bicarbonate level change
Timepoint [1] 422259 0
Change in serum bicarbonate level assessed immediately before and then 6-hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.
Secondary outcome [2] 422260 0
Serum base excess change
Timepoint [2] 422260 0
Change in serum base excess level assessed immediately before and then 6-hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.
Secondary outcome [3] 422261 0
Urinary chloride level change
Timepoint [3] 422261 0
Change in urinary chloride level assessed immediately before and then 6-hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.
Secondary outcome [4] 422262 0
Serum sodium level change
Timepoint [4] 422262 0
Change in serum sodium level assessed immediately before and then 6-hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.
Secondary outcome [5] 422263 0
Fluid balance effect
Timepoint [5] 422263 0
Change in fluid balance assessed immediately before and then 6-hours after diuretic administration while the patient is in the intensive care unit obtained from the medical record.

Eligibility
Key inclusion criteria
Adults aged 18 years or above
Physician decision to administer an intravenous diuretic;
Anticipated length of stay of more than 24 hours after intervention administration
Existing intra-arterial or central venous catheter
Existing indwelling urinary catheter
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Known allergy to furosemide or acetazolamide or other sulphonamides
known end-stage renal failure
Dose of any diuretic in the preceding 6 hours
Significant acid-base disturbance at time of enrolment (pH less than 7.25 or greater than 7.5)
Treatment with renal replacement therapy during this intensive care stay
Previously enrolled in this study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



The people analysing the results/data
Intervention assignment
Other design features
No other diuretics are to be administered to patients during the 6-hour study period following administration of diuretic therapy, unless clinically indicated by the patient’s treating intensive care unit physician.
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
Based on previous studies and observations in the intensive care, we assumed that using an alpha of 0.05 for significance, a study of 28 patients would have a greater than 80% power to detect a difference in urinary based on an expected urinary output of 500 ml over 6 hours (SD 200 ml) with furosemide and an increase to 710 ml with the addition of acetazolamide. We have increased the sample size to 30 patients to account for possible withdrawal of consent or data missingness.

We adopted will apply a Bayesian approach with linear regression analysis to describe the posterior probability distributions of the difference between groups in outcomes. In doing so we will be able to , providing more informative interpretations of our findings for future investigations or clinical decision-making. Using of the Bayesian approach is viewed as desirable as no previous literature has reported the 6-hour effects of adjunctive acetazolamide with furosemide and due to the small sample size of this study. We will utilize a non-informative flat prior distribution for all the outcomes of interest. Additionally, to evaluate change over time in UOP response to furosemide (ml/mg/hour), a linear mixed model will be employed with time from the administration and allocation group as fixed effects and patients as a random effect.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
23/05/2023
Date of last participant enrolment
Anticipated
31/12/2023
Actual
9/02/2024
Date of last data collection
Anticipated
30/06/2024
Actual
30/06/2024
Sample size
Target
30
Accrual to date
Final
31
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 24794 0
Austin Health - Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 40435 0
3084 - Heidelberg

Funding & Sponsors
Funding source category [1] 313918 0
Hospital
Name [1] 313918 0
Austin Health
Country [1] 313918 0
Australia
Primary sponsor type
Hospital
Name
Austin Hospital
Address
Austin Health
145 Studley Road
Heidelberg Victoria 3084
Country
Australia
Secondary sponsor category [1] 315779 0
Individual
Name [1] 315779 0
Professor Rinaldo Bellomo
Address [1] 315779 0
Department of Intensive Care
Austin Hospital
145 Studley Road
Heidelberg Victoria 3084
Country [1] 315779 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 313065 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 313065 0
Ethics committee country [1] 313065 0
Australia
Date submitted for ethics approval [1] 313065 0
24/03/2023
Approval date [1] 313065 0
14/04/2023
Ethics approval number [1] 313065 0
HREC/84325/Austin-2022

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 126866 0
Prof Rinaldo Bellomo
Address 126866 0
Director, Intensive Care Research
Department of Intensive Care
Austin Hospital
145 Studley Road
Heidelberg Victoria 3084
Country 126866 0
Australia
Phone 126866 0
+61394965992
Fax 126866 0
+61394963932
Email 126866 0
rinaldo.bellomo@austin.org.au
Contact person for public queries
Name 126867 0
Rinaldo Bellomo
Address 126867 0
Director, Intensive Care Research
Department of Intensive Care
Austin Hospital
145 Studley Road
Heidelberg Victoria 3084
Country 126867 0
Australia
Phone 126867 0
+61394965992
Fax 126867 0
+61394963932
Email 126867 0
rinaldo.bellomo@austin.org.au
Contact person for scientific queries
Name 126868 0
Rinaldo Bellomo
Address 126868 0
Director, Intensive Care Research
Department of Intensive Care
Austin Hospital
145 Studley Road
Heidelberg Victoria 3084
Country 126868 0
Australia
Phone 126868 0
+61394965992
Fax 126868 0
+61394963932
Email 126868 0
rinaldo.bellomo@austin.org.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
This is a pilot trial and results with be used to plan future trials and hypothesis-generating.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.